FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...
(Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases ...
FibroBiologics Inc. FBLG on Monday released the first batch of its CYWC628 drug product to support its Phase 1/2 clinical ...
FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...
On Wednesday, FibroBiologics, Inc. (NASDAQ: FBLG) submitted a new patent application with the U.S. Patent and Trademark Office (USPTO). The patent application covers a proprietary fibroblast-derived ...
Lung immune diseases have become a major global public health burden, with incidence increasing over the past two decades—especially in industrialized ...
Please provide your email address to receive an email when new articles are posted on . A master cell bank has been completed for a product that will utilize fibroblasts to treat chronic wounds.
The FDA granted breakthrough therapy designation to efimosfermin — an investigational, once-monthly fibroblast growth factor ...
The research group of Prof. Sanjiv Luther at the Department of Immunobiology of the University of Lausanne has discovered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results